Tarbox Family Office, Inc. Biomarin Pharmaceutical Inc Transaction History

Tarbox Family Office, Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 19, 2022	SELL	$71.48 - $86.85 $35,740 - $43,425	-500 Closed	0 $0
Q2 2021 Jul 16, 2021	SELL	$75.51 - $84.79 $830 - $932	-11 Reduced 2.15%	500 $42,000
Q1 2020 Apr 30, 2020	SELL	$71.37 - $96.85 $34,899 - $47,359	-489 Reduced 48.9%	511 $43,000
Q3 2019 Oct 25, 2019	SELL	$67.4 - $85.11 $1,348 - $1,702	-20 Reduced 1.96%	1,000 $67,000
Q4 2018 Feb 01, 2019	SELL	$80.14 - $106.07 $240 - $318	-3 Reduced 0.29%	1,020 $87,000
Q2 2018 Jul 31, 2018	BUY	$76.01 - $99.03 $228 - $297	3 Added 0.29%	1,023 $96,000
Q3 2017 Oct 19, 2017	BUY	$80.6 - $94.95 $82,212 - $96,849	1,020	1,020 $95,000

632

185M

1.63M

1.2M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $13.1B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Tarbox Family Office, Inc., based on Form 13F filings with the SEC.

Stay updated on Tarbox Family Office, Inc. with notifications on news.